Royalty Pharma, RPRX and NASDAQ

Royalty Pharma (NASDAQ:RPRX) Misses Q4 Revenue Estimates
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) missed Wall Street’s revenue expectations in Q4 CY2024, with sales flat year on year at $594 million. Its GAAP profit of $0.57 per share was significantly above analysts’ consensus estimates.
Royalty Pharma plc (NASDAQ:RPRX) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 11, 2025 Royalty Pharma plc misses on earnings expectations. Reported EPS is $0.3509 EPS, expectations were $0.99. Operator: Ladies and gentlemen, thank you for standing by,
Royalty Pharma Reports Q4 and Full Year 2024 Results
Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net
Royalty Pharma: Q4 Earnings Snapshot
The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of $1.09 per share. The company posted revenue of $594 million in the period. Its adjusted revenue was $742 million.
Royalty Pharma targets $3B share buyback and projects 4-9% growth in 2025 portfolio receipts
Q4 2024 Management View CEO Pablo Legorreta highlighted strong 2024 performance, reporting $2.8 billion in portfolio receipts, at the high end of guidance and reflecting 13% growth in Royalty Receipts.
Royalty Pharma reports Q4 portfolio receipts of $742M
Royalty Receipts grew 12% to $729 million in the fourth quarter and 13% to $2,771 million for full year 2024, driven by strong performance from
Earnings call transcript: Royalty Pharma Q4 2024 misses EPS forecast
Royalty Pharma Plc (RPRX) reported its Q4 2024 earnings today, revealing earnings per share (EPS) of $0.3531, falling short of the forecasted $0.9849. The company also reported revenue of $594 million,
Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q4 Earnings
Royalty Pharma (RPRX) reported $742 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 0.8%. EPS of $1.15 for the same period compares to $1.15 a year ago.
GlobalData on MSN2d
Royalty Pharma pays $250m for rights to Biogen’s lupus drug
Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...
Royalty Pharma: Delivering Growth With A Positive Story Ahead
Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million. Read why RPRX ...
FierceBiotech3d
Biogen enlists Royalty for pursuit of lupus crown, securing $250M to fund phase 3 program
Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...
BioSpace3d
Biogen Taps Royalty Pharma for $250M to Power Phase III Lupus Program
The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...
BioPharma Dive3d
Biogen inks royalty deal to gain funding for lupus drug R&D
The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, ...
Royalty Pharma plc (RPRX): A Cheap Biotech Stock to Invest In Now
We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...
Royalty Pharma Announces R&D Funding Collaboration With Biogen
We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...
The Pharma Letter3d
Royalty Pharma inks R&D funding deal with Biogen
Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding for the US biotech ...
Hosted on MSN2d
Royalty Pharma’s Internalization Strategy: Navigating Risks and Uncertainties Ahead of 2025 Transition
Royalty Pharma PLC (RPRX) has disclosed a new risk, in the Regulation category. The planned internalization of Royalty Pharma LLC by RP Holdings, ...